nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Carboplatin—esophageal cancer	0.159	0.298	CbGbCtD
Leflunomide—ABCG2—Cisplatin—esophageal cancer	0.136	0.255	CbGbCtD
Leflunomide—CYP2C9—Capecitabine—esophageal cancer	0.1	0.188	CbGbCtD
Leflunomide—ABCG2—Methotrexate—esophageal cancer	0.0883	0.165	CbGbCtD
Leflunomide—CYP2C9—Cisplatin—esophageal cancer	0.0505	0.0946	CbGbCtD
Leflunomide—DHODH—lung—esophageal cancer	0.00402	0.108	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—esophageal cancer	0.00387	0.104	CbGeAlD
Leflunomide—Niflumic Acid—PTGS1—esophageal cancer	0.00369	0.636	CrCbGaD
Leflunomide—AHR—bronchus—esophageal cancer	0.00325	0.087	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—esophageal cancer	0.00318	0.0851	CbGeAlD
Leflunomide—PTK2B—digestive system—esophageal cancer	0.00305	0.0817	CbGeAlD
Leflunomide—AHR—trachea—esophageal cancer	0.00292	0.0781	CbGeAlD
Leflunomide—DHODH—lymph node—esophageal cancer	0.00275	0.0737	CbGeAlD
Leflunomide—PTK2B—lung—esophageal cancer	0.00255	0.0683	CbGeAlD
Leflunomide—AHR—digestive system—esophageal cancer	0.00251	0.0672	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—esophageal cancer	0.00211	0.364	CrCbGaD
Leflunomide—AHR—lung—esophageal cancer	0.0021	0.0561	CbGeAlD
Leflunomide—PTK2B—lymph node—esophageal cancer	0.00174	0.0467	CbGeAlD
Leflunomide—AHR—lymph node—esophageal cancer	0.00143	0.0384	CbGeAlD
Leflunomide—CYP1A2—digestive system—esophageal cancer	0.000937	0.0251	CbGeAlD
Leflunomide—CYP2C9—digestive system—esophageal cancer	0.000889	0.0238	CbGeAlD
Leflunomide—ABCG2—lung—esophageal cancer	0.000813	0.0218	CbGeAlD
Leflunomide—CYP1A2—lung—esophageal cancer	0.000782	0.0209	CbGeAlD
Leflunomide—Renal failure—Cisplatin—esophageal cancer	0.000686	0.0033	CcSEcCtD
Leflunomide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000684	0.00329	CcSEcCtD
Leflunomide—Stomatitis—Cisplatin—esophageal cancer	0.000681	0.00327	CcSEcCtD
Leflunomide—Conjunctivitis—Cisplatin—esophageal cancer	0.000679	0.00326	CcSEcCtD
Leflunomide—Melaena—Methotrexate—esophageal cancer	0.000669	0.00322	CcSEcCtD
Leflunomide—Cystitis noninfective—Methotrexate—esophageal cancer	0.000669	0.00322	CcSEcCtD
Leflunomide—Osteoarthritis—Capecitabine—esophageal cancer	0.000668	0.00321	CcSEcCtD
Leflunomide—Cystitis—Methotrexate—esophageal cancer	0.000661	0.00318	CcSEcCtD
Leflunomide—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00066	0.00317	CcSEcCtD
Leflunomide—Migraine—Capecitabine—esophageal cancer	0.000657	0.00316	CcSEcCtD
Leflunomide—Neoplasm—Methotrexate—esophageal cancer	0.000619	0.00298	CcSEcCtD
Leflunomide—Bladder pain—Methotrexate—esophageal cancer	0.000619	0.00298	CcSEcCtD
Leflunomide—Ecchymosis—Methotrexate—esophageal cancer	0.000619	0.00298	CcSEcCtD
Leflunomide—Mouth ulceration—Methotrexate—esophageal cancer	0.000619	0.00298	CcSEcCtD
Leflunomide—Urinary tract disorder—Cisplatin—esophageal cancer	0.000619	0.00298	CcSEcCtD
Leflunomide—Liver function test abnormal—Capecitabine—esophageal cancer	0.000617	0.00296	CcSEcCtD
Leflunomide—Connective tissue disorder—Cisplatin—esophageal cancer	0.000616	0.00296	CcSEcCtD
Leflunomide—Urethral disorder—Cisplatin—esophageal cancer	0.000614	0.00295	CcSEcCtD
Leflunomide—Dry skin—Capecitabine—esophageal cancer	0.000612	0.00294	CcSEcCtD
Leflunomide—Hypokalaemia—Capecitabine—esophageal cancer	0.000608	0.00292	CcSEcCtD
Leflunomide—Breast disorder—Capecitabine—esophageal cancer	0.000603	0.0029	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000601	0.00289	CcSEcCtD
Leflunomide—Sepsis—Methotrexate—esophageal cancer	0.000594	0.00286	CcSEcCtD
Leflunomide—Gastritis—Capecitabine—esophageal cancer	0.000591	0.00284	CcSEcCtD
Leflunomide—Eye disorder—Cisplatin—esophageal cancer	0.000586	0.00282	CcSEcCtD
Leflunomide—Lymphadenopathy—Methotrexate—esophageal cancer	0.000583	0.0028	CcSEcCtD
Leflunomide—Cardiac disorder—Cisplatin—esophageal cancer	0.000582	0.0028	CcSEcCtD
Leflunomide—Asthma—Capecitabine—esophageal cancer	0.000577	0.00278	CcSEcCtD
Leflunomide—Influenza—Capecitabine—esophageal cancer	0.000577	0.00278	CcSEcCtD
Leflunomide—Diabetes mellitus—Methotrexate—esophageal cancer	0.000572	0.00275	CcSEcCtD
Leflunomide—Immune system disorder—Cisplatin—esophageal cancer	0.000566	0.00272	CcSEcCtD
Leflunomide—Mediastinal disorder—Cisplatin—esophageal cancer	0.000565	0.00272	CcSEcCtD
Leflunomide—Sweating increased—Capecitabine—esophageal cancer	0.000562	0.0027	CcSEcCtD
Leflunomide—Angina pectoris—Capecitabine—esophageal cancer	0.000562	0.0027	CcSEcCtD
Leflunomide—Arrhythmia—Cisplatin—esophageal cancer	0.00056	0.00269	CcSEcCtD
Leflunomide—ABCG2—lymph node—esophageal cancer	0.000556	0.0149	CbGeAlD
Leflunomide—Bronchitis—Capecitabine—esophageal cancer	0.000555	0.00267	CcSEcCtD
Leflunomide—Alopecia—Cisplatin—esophageal cancer	0.000554	0.00266	CcSEcCtD
Leflunomide—Hepatic failure—Methotrexate—esophageal cancer	0.000553	0.00266	CcSEcCtD
Leflunomide—Pancytopenia—Capecitabine—esophageal cancer	0.000548	0.00264	CcSEcCtD
Leflunomide—Malnutrition—Cisplatin—esophageal cancer	0.000546	0.00262	CcSEcCtD
Leflunomide—Dysuria—Capecitabine—esophageal cancer	0.00054	0.00259	CcSEcCtD
Leflunomide—Neutropenia—Capecitabine—esophageal cancer	0.00054	0.00259	CcSEcCtD
Leflunomide—Flatulence—Cisplatin—esophageal cancer	0.000538	0.00258	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000536	0.00258	CcSEcCtD
Leflunomide—Muscle spasms—Cisplatin—esophageal cancer	0.000525	0.00252	CcSEcCtD
Leflunomide—Weight decreased—Capecitabine—esophageal cancer	0.000522	0.00251	CcSEcCtD
Leflunomide—Hyperglycaemia—Capecitabine—esophageal cancer	0.000521	0.0025	CcSEcCtD
Leflunomide—Pneumonia—Capecitabine—esophageal cancer	0.000518	0.00249	CcSEcCtD
Leflunomide—Infestation NOS—Capecitabine—esophageal cancer	0.000515	0.00247	CcSEcCtD
Leflunomide—Infestation—Capecitabine—esophageal cancer	0.000515	0.00247	CcSEcCtD
Leflunomide—Vision blurred—Cisplatin—esophageal cancer	0.000514	0.00247	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000514	0.00247	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00051	0.00245	CcSEcCtD
Leflunomide—Ill-defined disorder—Cisplatin—esophageal cancer	0.000506	0.00243	CcSEcCtD
Leflunomide—Renal failure—Capecitabine—esophageal cancer	0.000506	0.00243	CcSEcCtD
Leflunomide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000504	0.00243	CcSEcCtD
Leflunomide—Anaemia—Cisplatin—esophageal cancer	0.000504	0.00242	CcSEcCtD
Leflunomide—Jaundice—Capecitabine—esophageal cancer	0.000502	0.00241	CcSEcCtD
Leflunomide—Stomatitis—Capecitabine—esophageal cancer	0.000502	0.00241	CcSEcCtD
Leflunomide—Urinary tract infection—Capecitabine—esophageal cancer	0.0005	0.00241	CcSEcCtD
Leflunomide—Conjunctivitis—Capecitabine—esophageal cancer	0.0005	0.00241	CcSEcCtD
Leflunomide—Osteoarthritis—Methotrexate—esophageal cancer	0.000497	0.00239	CcSEcCtD
Leflunomide—Malaise—Cisplatin—esophageal cancer	0.000492	0.00237	CcSEcCtD
Leflunomide—Haematuria—Capecitabine—esophageal cancer	0.000491	0.00236	CcSEcCtD
Leflunomide—Leukopenia—Cisplatin—esophageal cancer	0.000488	0.00235	CcSEcCtD
Leflunomide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000487	0.00234	CcSEcCtD
Leflunomide—Epistaxis—Capecitabine—esophageal cancer	0.000485	0.00233	CcSEcCtD
Leflunomide—Agranulocytosis—Capecitabine—esophageal cancer	0.00048	0.00231	CcSEcCtD
Leflunomide—Myalgia—Cisplatin—esophageal cancer	0.000464	0.00223	CcSEcCtD
Leflunomide—Haemoglobin—Capecitabine—esophageal cancer	0.000464	0.00223	CcSEcCtD
Leflunomide—Rhinitis—Capecitabine—esophageal cancer	0.000463	0.00223	CcSEcCtD
Leflunomide—Anxiety—Cisplatin—esophageal cancer	0.000463	0.00223	CcSEcCtD
Leflunomide—Hepatitis—Capecitabine—esophageal cancer	0.000462	0.00222	CcSEcCtD
Leflunomide—Haemorrhage—Capecitabine—esophageal cancer	0.000462	0.00222	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000461	0.00222	CcSEcCtD
Leflunomide—Liver function test abnormal—Methotrexate—esophageal cancer	0.000459	0.00221	CcSEcCtD
Leflunomide—Discomfort—Cisplatin—esophageal cancer	0.000459	0.00221	CcSEcCtD
Leflunomide—Pharyngitis—Capecitabine—esophageal cancer	0.000459	0.0022	CcSEcCtD
Leflunomide—Urinary tract disorder—Capecitabine—esophageal cancer	0.000456	0.00219	CcSEcCtD
Leflunomide—Oedema peripheral—Capecitabine—esophageal cancer	0.000455	0.00219	CcSEcCtD
Leflunomide—Connective tissue disorder—Capecitabine—esophageal cancer	0.000454	0.00218	CcSEcCtD
Leflunomide—Urethral disorder—Capecitabine—esophageal cancer	0.000453	0.00218	CcSEcCtD
Leflunomide—Breast disorder—Methotrexate—esophageal cancer	0.000449	0.00216	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000448	0.00215	CcSEcCtD
Leflunomide—Anaphylactic shock—Cisplatin—esophageal cancer	0.000445	0.00214	CcSEcCtD
Leflunomide—Infection—Cisplatin—esophageal cancer	0.000442	0.00213	CcSEcCtD
Leflunomide—Erythema multiforme—Capecitabine—esophageal cancer	0.000437	0.0021	CcSEcCtD
Leflunomide—Nervous system disorder—Cisplatin—esophageal cancer	0.000437	0.0021	CcSEcCtD
Leflunomide—Thrombocytopenia—Cisplatin—esophageal cancer	0.000436	0.0021	CcSEcCtD
Leflunomide—Tachycardia—Cisplatin—esophageal cancer	0.000435	0.00209	CcSEcCtD
Leflunomide—Skin disorder—Cisplatin—esophageal cancer	0.000432	0.00208	CcSEcCtD
Leflunomide—Eye disorder—Capecitabine—esophageal cancer	0.000432	0.00208	CcSEcCtD
Leflunomide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00043	0.00207	CcSEcCtD
Leflunomide—Asthma—Methotrexate—esophageal cancer	0.00043	0.00207	CcSEcCtD
Leflunomide—Cardiac disorder—Capecitabine—esophageal cancer	0.000429	0.00206	CcSEcCtD
Leflunomide—Eosinophilia—Methotrexate—esophageal cancer	0.000425	0.00205	CcSEcCtD
Leflunomide—Anorexia—Cisplatin—esophageal cancer	0.000424	0.00204	CcSEcCtD
Leflunomide—Pancreatitis—Methotrexate—esophageal cancer	0.000421	0.00203	CcSEcCtD
Leflunomide—Immune system disorder—Capecitabine—esophageal cancer	0.000417	0.00201	CcSEcCtD
Leflunomide—Mediastinal disorder—Capecitabine—esophageal cancer	0.000416	0.002	CcSEcCtD
Leflunomide—Hypotension—Cisplatin—esophageal cancer	0.000416	0.002	CcSEcCtD
Leflunomide—Chills—Capecitabine—esophageal cancer	0.000415	0.00199	CcSEcCtD
Leflunomide—Arrhythmia—Capecitabine—esophageal cancer	0.000413	0.00198	CcSEcCtD
Leflunomide—Alopecia—Capecitabine—esophageal cancer	0.000408	0.00196	CcSEcCtD
Leflunomide—Pancytopenia—Methotrexate—esophageal cancer	0.000408	0.00196	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000406	0.00195	CcSEcCtD
Leflunomide—Mental disorder—Capecitabine—esophageal cancer	0.000405	0.00195	CcSEcCtD
Leflunomide—Malnutrition—Capecitabine—esophageal cancer	0.000402	0.00193	CcSEcCtD
Leflunomide—Dysuria—Methotrexate—esophageal cancer	0.000402	0.00193	CcSEcCtD
Leflunomide—Neutropenia—Methotrexate—esophageal cancer	0.000402	0.00193	CcSEcCtD
Leflunomide—Paraesthesia—Cisplatin—esophageal cancer	0.0004	0.00192	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000399	0.00192	CcSEcCtD
Leflunomide—Dyspnoea—Cisplatin—esophageal cancer	0.000397	0.00191	CcSEcCtD
Leflunomide—Flatulence—Capecitabine—esophageal cancer	0.000396	0.00191	CcSEcCtD
Leflunomide—Dysgeusia—Capecitabine—esophageal cancer	0.000394	0.00189	CcSEcCtD
Leflunomide—Back pain—Capecitabine—esophageal cancer	0.000389	0.00187	CcSEcCtD
Leflunomide—Decreased appetite—Cisplatin—esophageal cancer	0.000387	0.00186	CcSEcCtD
Leflunomide—Muscle spasms—Capecitabine—esophageal cancer	0.000387	0.00186	CcSEcCtD
Leflunomide—Pneumonia—Methotrexate—esophageal cancer	0.000385	0.00185	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000384	0.00185	CcSEcCtD
Leflunomide—Infestation—Methotrexate—esophageal cancer	0.000383	0.00184	CcSEcCtD
Leflunomide—Infestation NOS—Methotrexate—esophageal cancer	0.000383	0.00184	CcSEcCtD
Leflunomide—Pain—Cisplatin—esophageal cancer	0.000381	0.00183	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00038	0.00183	CcSEcCtD
Leflunomide—Vision blurred—Capecitabine—esophageal cancer	0.000379	0.00182	CcSEcCtD
Leflunomide—Renal failure—Methotrexate—esophageal cancer	0.000377	0.00181	CcSEcCtD
Leflunomide—Stomatitis—Methotrexate—esophageal cancer	0.000373	0.0018	CcSEcCtD
Leflunomide—Ill-defined disorder—Capecitabine—esophageal cancer	0.000373	0.00179	CcSEcCtD
Leflunomide—Conjunctivitis—Methotrexate—esophageal cancer	0.000372	0.00179	CcSEcCtD
Leflunomide—Anaemia—Capecitabine—esophageal cancer	0.000372	0.00179	CcSEcCtD
Leflunomide—Feeling abnormal—Cisplatin—esophageal cancer	0.000367	0.00176	CcSEcCtD
Leflunomide—Haematuria—Methotrexate—esophageal cancer	0.000365	0.00176	CcSEcCtD
Leflunomide—Malaise—Capecitabine—esophageal cancer	0.000363	0.00174	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000362	0.00174	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—esophageal cancer	0.000361	0.00174	CcSEcCtD
Leflunomide—Vertigo—Capecitabine—esophageal cancer	0.000361	0.00174	CcSEcCtD
Leflunomide—Leukopenia—Capecitabine—esophageal cancer	0.00036	0.00173	CcSEcCtD
Leflunomide—Agranulocytosis—Methotrexate—esophageal cancer	0.000358	0.00172	CcSEcCtD
Leflunomide—Palpitations—Capecitabine—esophageal cancer	0.000355	0.00171	CcSEcCtD
Leflunomide—Body temperature increased—Cisplatin—esophageal cancer	0.000352	0.00169	CcSEcCtD
Leflunomide—Cough—Capecitabine—esophageal cancer	0.000351	0.00169	CcSEcCtD
Leflunomide—Hypertension—Capecitabine—esophageal cancer	0.000347	0.00167	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—esophageal cancer	0.000346	0.00166	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—esophageal cancer	0.000344	0.00165	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—esophageal cancer	0.000344	0.00165	CcSEcCtD
Leflunomide—Myalgia—Capecitabine—esophageal cancer	0.000342	0.00165	CcSEcCtD
Leflunomide—Arthralgia—Capecitabine—esophageal cancer	0.000342	0.00165	CcSEcCtD
Leflunomide—Chest pain—Capecitabine—esophageal cancer	0.000342	0.00165	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—esophageal cancer	0.000341	0.00164	CcSEcCtD
Leflunomide—Anxiety—Capecitabine—esophageal cancer	0.000341	0.00164	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00034	0.00163	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00034	0.00163	CcSEcCtD
Leflunomide—Discomfort—Capecitabine—esophageal cancer	0.000338	0.00163	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—esophageal cancer	0.000337	0.00162	CcSEcCtD
Leflunomide—Dry mouth—Capecitabine—esophageal cancer	0.000335	0.00161	CcSEcCtD
Leflunomide—Hypersensitivity—Cisplatin—esophageal cancer	0.000328	0.00158	CcSEcCtD
Leflunomide—Infection—Capecitabine—esophageal cancer	0.000326	0.00157	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—esophageal cancer	0.000325	0.00156	CcSEcCtD
Leflunomide—Nervous system disorder—Capecitabine—esophageal cancer	0.000322	0.00155	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—esophageal cancer	0.000321	0.00155	CcSEcCtD
Leflunomide—Thrombocytopenia—Capecitabine—esophageal cancer	0.000321	0.00155	CcSEcCtD
Leflunomide—Tachycardia—Capecitabine—esophageal cancer	0.00032	0.00154	CcSEcCtD
Leflunomide—Asthenia—Cisplatin—esophageal cancer	0.000319	0.00154	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—esophageal cancer	0.000319	0.00153	CcSEcCtD
Leflunomide—Skin disorder—Capecitabine—esophageal cancer	0.000319	0.00153	CcSEcCtD
Leflunomide—Hyperhidrosis—Capecitabine—esophageal cancer	0.000317	0.00153	CcSEcCtD
Leflunomide—Anorexia—Capecitabine—esophageal cancer	0.000313	0.0015	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—esophageal cancer	0.000311	0.00149	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—esophageal cancer	0.00031	0.00149	CcSEcCtD
Leflunomide—Chills—Methotrexate—esophageal cancer	0.000309	0.00148	CcSEcCtD
Leflunomide—Hypotension—Capecitabine—esophageal cancer	0.000307	0.00147	CcSEcCtD
Leflunomide—Diarrhoea—Cisplatin—esophageal cancer	0.000305	0.00146	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—esophageal cancer	0.000304	0.00146	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—esophageal cancer	0.000301	0.00145	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—esophageal cancer	0.000299	0.00144	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000299	0.00144	CcSEcCtD
Leflunomide—Insomnia—Capecitabine—esophageal cancer	0.000297	0.00143	CcSEcCtD
Leflunomide—Paraesthesia—Capecitabine—esophageal cancer	0.000295	0.00142	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—esophageal cancer	0.000293	0.00141	CcSEcCtD
Leflunomide—Dyspnoea—Capecitabine—esophageal cancer	0.000293	0.00141	CcSEcCtD
Leflunomide—Back pain—Methotrexate—esophageal cancer	0.00029	0.00139	CcSEcCtD
Leflunomide—Dyspepsia—Capecitabine—esophageal cancer	0.000289	0.00139	CcSEcCtD
Leflunomide—Decreased appetite—Capecitabine—esophageal cancer	0.000285	0.00137	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000283	0.00136	CcSEcCtD
Leflunomide—Vomiting—Cisplatin—esophageal cancer	0.000283	0.00136	CcSEcCtD
Leflunomide—Fatigue—Capecitabine—esophageal cancer	0.000283	0.00136	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—esophageal cancer	0.000282	0.00136	CcSEcCtD
Leflunomide—Rash—Cisplatin—esophageal cancer	0.000281	0.00135	CcSEcCtD
Leflunomide—Constipation—Capecitabine—esophageal cancer	0.000281	0.00135	CcSEcCtD
Leflunomide—Pain—Capecitabine—esophageal cancer	0.000281	0.00135	CcSEcCtD
Leflunomide—Dermatitis—Cisplatin—esophageal cancer	0.00028	0.00135	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—esophageal cancer	0.000278	0.00134	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—esophageal cancer	0.000277	0.00133	CcSEcCtD
Leflunomide—Feeling abnormal—Capecitabine—esophageal cancer	0.00027	0.0013	CcSEcCtD
Leflunomide—Malaise—Methotrexate—esophageal cancer	0.00027	0.0013	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—esophageal cancer	0.000269	0.00129	CcSEcCtD
Leflunomide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000268	0.00129	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—esophageal cancer	0.000268	0.00129	CcSEcCtD
Leflunomide—Nausea—Cisplatin—esophageal cancer	0.000264	0.00127	CcSEcCtD
Leflunomide—Cough—Methotrexate—esophageal cancer	0.000261	0.00126	CcSEcCtD
Leflunomide—Urticaria—Capecitabine—esophageal cancer	0.000261	0.00125	CcSEcCtD
Leflunomide—Abdominal pain—Capecitabine—esophageal cancer	0.000259	0.00125	CcSEcCtD
Leflunomide—Body temperature increased—Capecitabine—esophageal cancer	0.000259	0.00125	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—esophageal cancer	0.000255	0.00123	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—esophageal cancer	0.000255	0.00123	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—esophageal cancer	0.000255	0.00123	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000253	0.00122	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—esophageal cancer	0.000252	0.00121	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—esophageal cancer	0.000244	0.00117	CcSEcCtD
Leflunomide—Infection—Methotrexate—esophageal cancer	0.000243	0.00117	CcSEcCtD
Leflunomide—Hypersensitivity—Capecitabine—esophageal cancer	0.000242	0.00116	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—esophageal cancer	0.00024	0.00115	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000239	0.00115	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—esophageal cancer	0.000237	0.00114	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—esophageal cancer	0.000236	0.00114	CcSEcCtD
Leflunomide—Asthenia—Capecitabine—esophageal cancer	0.000235	0.00113	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—esophageal cancer	0.000233	0.00112	CcSEcCtD
Leflunomide—Pruritus—Capecitabine—esophageal cancer	0.000232	0.00112	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—esophageal cancer	0.000228	0.0011	CcSEcCtD
Leflunomide—Diarrhoea—Capecitabine—esophageal cancer	0.000225	0.00108	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000223	0.00107	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—esophageal cancer	0.000221	0.00106	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—esophageal cancer	0.000219	0.00105	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—esophageal cancer	0.000218	0.00105	CcSEcCtD
Leflunomide—Dizziness—Capecitabine—esophageal cancer	0.000217	0.00104	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000216	0.001	CbGpPWpGaD
Leflunomide—Dyspepsia—Methotrexate—esophageal cancer	0.000215	0.00103	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000215	0.001	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000214	0.000996	CbGpPWpGaD
Leflunomide—Decreased appetite—Methotrexate—esophageal cancer	0.000212	0.00102	CcSEcCtD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000211	0.000983	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000211	0.00101	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—esophageal cancer	0.000211	0.00101	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—TP53—esophageal cancer	0.000211	0.000981	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.00021	0.000979	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000209	0.000974	CbGpPWpGaD
Leflunomide—Pain—Methotrexate—esophageal cancer	0.000209	0.001	CcSEcCtD
Leflunomide—Vomiting—Capecitabine—esophageal cancer	0.000209	0.001	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000208	0.000969	CbGpPWpGaD
Leflunomide—Rash—Capecitabine—esophageal cancer	0.000207	0.000995	CcSEcCtD
Leflunomide—Dermatitis—Capecitabine—esophageal cancer	0.000207	0.000994	CcSEcCtD
Leflunomide—DHODH—Metabolism—HMOX1—esophageal cancer	0.000206	0.000959	CbGpPWpGaD
Leflunomide—Headache—Capecitabine—esophageal cancer	0.000206	0.000989	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000203	0.000945	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000202	0.000943	CbGpPWpGaD
Leflunomide—Feeling abnormal—Methotrexate—esophageal cancer	0.000201	0.000968	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.0002	0.000961	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.0002	0.000929	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PIK3CA—esophageal cancer	0.000198	0.000922	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ABCB1—esophageal cancer	0.000198	0.00092	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000197	0.000917	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KMT2D—esophageal cancer	0.000197	0.000916	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—PIK3CA—esophageal cancer	0.000196	0.000915	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000196	0.000911	CbGpPWpGaD
Leflunomide—Nausea—Capecitabine—esophageal cancer	0.000195	0.000937	CcSEcCtD
Leflunomide—Urticaria—Methotrexate—esophageal cancer	0.000194	0.000933	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—esophageal cancer	0.000193	0.000929	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—esophageal cancer	0.000193	0.000929	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—PIK3CA—esophageal cancer	0.000187	0.00087	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000186	0.000864	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000186	0.000864	CbGpPWpGaD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000184	0.000859	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000183	0.000854	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000183	0.000852	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000183	0.000852	CbGpPWpGaD
Leflunomide—Hypersensitivity—Methotrexate—esophageal cancer	0.00018	0.000866	CcSEcCtD
Leflunomide—PTK2B—Immune System—ELMO1—esophageal cancer	0.000179	0.000833	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000177	0.000824	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ADCYAP1—esophageal cancer	0.000175	0.000817	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—esophageal cancer	0.000175	0.000843	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000173	0.000807	CbGpPWpGaD
Leflunomide—Pruritus—Methotrexate—esophageal cancer	0.000173	0.000831	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000171	0.000794	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00017	0.00079	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00017	0.00079	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—PIK3CA—esophageal cancer	0.000169	0.000789	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000168	0.000783	CbGpPWpGaD
Leflunomide—Diarrhoea—Methotrexate—esophageal cancer	0.000167	0.000804	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—esophageal cancer	0.000164	0.000762	CbGpPWpGaD
Leflunomide—Dizziness—Methotrexate—esophageal cancer	0.000162	0.000777	CcSEcCtD
Leflunomide—PTK2B—Immune System—CFL1—esophageal cancer	0.000161	0.000751	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—WWOX—esophageal cancer	0.00016	0.000747	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000159	0.000738	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000156	0.000728	CbGpPWpGaD
Leflunomide—Vomiting—Methotrexate—esophageal cancer	0.000155	0.000747	CcSEcCtD
Leflunomide—PTK2B—Immune System—LGALS3—esophageal cancer	0.000154	0.000719	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000154	0.000718	CbGpPWpGaD
Leflunomide—Rash—Methotrexate—esophageal cancer	0.000154	0.000741	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—esophageal cancer	0.000154	0.00074	CcSEcCtD
Leflunomide—Headache—Methotrexate—esophageal cancer	0.000153	0.000736	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—FKBP1A—esophageal cancer	0.000153	0.00071	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000151	0.000704	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—WIF1—esophageal cancer	0.000149	0.000694	CbGpPWpGaD
Leflunomide—Nausea—Methotrexate—esophageal cancer	0.000145	0.000698	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000144	0.00067	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000142	0.000662	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000139	0.000646	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000138	0.000641	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ACTB—esophageal cancer	0.000137	0.000639	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000135	0.000628	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTPN2—esophageal cancer	0.000134	0.000624	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—B2M—esophageal cancer	0.000132	0.000617	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CREBBP—esophageal cancer	0.000132	0.000615	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000129	0.000602	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PFN1—esophageal cancer	0.000129	0.000599	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000129	0.000599	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000127	0.00059	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PSME2—esophageal cancer	0.000125	0.000583	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PSME1—esophageal cancer	0.000125	0.000583	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HSPA5—esophageal cancer	0.000124	0.000577	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000123	0.000573	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000122	0.000566	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CALR—esophageal cancer	0.00012	0.000559	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000119	0.000552	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NOS3—esophageal cancer	0.000118	0.000551	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000117	0.000543	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FBXW7—esophageal cancer	0.000116	0.000541	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ELMO1—esophageal cancer	0.000116	0.000538	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000115	0.000536	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BLVRB—esophageal cancer	0.000115	0.000534	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC52A3—esophageal cancer	0.000115	0.000534	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000115	0.000534	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000113	0.000526	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKAP13—esophageal cancer	0.000113	0.000526	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HMGB1—esophageal cancer	0.000111	0.000517	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000111	0.000516	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000111	0.000515	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—esophageal cancer	0.000108	0.000504	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000108	0.000502	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000106	0.000495	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000105	0.000491	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000105	0.000491	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000104	0.000486	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDE4D—esophageal cancer	0.000103	0.000481	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GNG7—esophageal cancer	9.83e-05	0.000458	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	9.79e-05	0.000456	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CA1—esophageal cancer	9.75e-05	0.000454	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC10A2—esophageal cancer	9.75e-05	0.000454	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	9.66e-05	0.00045	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	9.45e-05	0.00044	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—XIAP—esophageal cancer	9.21e-05	0.000429	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	9.21e-05	0.000429	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	9.19e-05	0.000428	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ABL1—esophageal cancer	9.18e-05	0.000428	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	9.17e-05	0.000427	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	9.08e-05	0.000423	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—EP300—esophageal cancer	8.99e-05	0.000419	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	8.99e-05	0.000419	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	8.99e-05	0.000419	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CA2—esophageal cancer	8.92e-05	0.000415	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNA1—esophageal cancer	8.71e-05	0.000406	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL2—esophageal cancer	8.66e-05	0.000403	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ADH7—esophageal cancer	8.29e-05	0.000386	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLCE1—esophageal cancer	8.29e-05	0.000386	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSME2—esophageal cancer	8.09e-05	0.000377	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSME1—esophageal cancer	8.09e-05	0.000377	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ANXA1—esophageal cancer	8.05e-05	0.000375	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SST—esophageal cancer	7.83e-05	0.000365	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH3—esophageal cancer	7.63e-05	0.000355	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GHRL—esophageal cancer	7.63e-05	0.000355	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FBXW7—esophageal cancer	7.51e-05	0.00035	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.47e-05	0.000348	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ADH1B—esophageal cancer	7.27e-05	0.000339	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	7.11e-05	0.000331	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—esophageal cancer	6.96e-05	0.000324	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMP—esophageal cancer	6.95e-05	0.000323	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH2—esophageal cancer	6.85e-05	0.000319	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	6.82e-05	0.000318	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP26A1—esophageal cancer	6.76e-05	0.000315	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—esophageal cancer	6.65e-05	0.00031	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALOX15—esophageal cancer	6.58e-05	0.000307	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.52e-05	0.000303	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	6.38e-05	0.000297	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTO1—esophageal cancer	6.28e-05	0.000293	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TPI1—esophageal cancer	6.28e-05	0.000293	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFBR2—esophageal cancer	6.07e-05	0.000283	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALDOB—esophageal cancer	6.02e-05	0.00028	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CASP8—esophageal cancer	5.97e-05	0.000278	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CREBBP—esophageal cancer	5.94e-05	0.000277	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GAPDH—esophageal cancer	5.8e-05	0.00027	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC52A3—esophageal cancer	5.79e-05	0.00027	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BLVRB—esophageal cancer	5.79e-05	0.00027	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SMAD4—esophageal cancer	5.75e-05	0.000268	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CRABP1—esophageal cancer	5.75e-05	0.000268	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	5.57e-05	0.000259	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNG7—esophageal cancer	5.46e-05	0.000255	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.18e-05	0.000241	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2—esophageal cancer	5.12e-05	0.000239	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALDH2—esophageal cancer	5.12e-05	0.000238	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—esophageal cancer	4.98e-05	0.000232	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BLVRB—esophageal cancer	4.95e-05	0.00023	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC52A3—esophageal cancer	4.95e-05	0.00023	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC10A2—esophageal cancer	4.92e-05	0.000229	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA1—esophageal cancer	4.92e-05	0.000229	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTT1—esophageal cancer	4.87e-05	0.000227	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2A6—esophageal cancer	4.81e-05	0.000224	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—esophageal cancer	4.7e-05	0.000219	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS1—esophageal cancer	4.56e-05	0.000213	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO1—esophageal cancer	4.56e-05	0.000213	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.56e-05	0.000212	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA2—esophageal cancer	4.5e-05	0.00021	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—esophageal cancer	4.5e-05	0.000209	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSME2—esophageal cancer	4.5e-05	0.000209	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSME1—esophageal cancer	4.5e-05	0.000209	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.42e-05	0.000206	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.4e-05	0.000205	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—esophageal cancer	4.25e-05	0.000198	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH1—esophageal cancer	4.24e-05	0.000197	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CA1—esophageal cancer	4.21e-05	0.000196	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC10A2—esophageal cancer	4.21e-05	0.000196	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ADH7—esophageal cancer	4.19e-05	0.000195	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLCE1—esophageal cancer	4.19e-05	0.000195	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.14e-05	0.000193	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—esophageal cancer	4.05e-05	0.000188	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1B1—esophageal cancer	3.88e-05	0.000181	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CA2—esophageal cancer	3.85e-05	0.000179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CREBBP—esophageal cancer	3.84e-05	0.000179	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.76e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ADH1B—esophageal cancer	3.67e-05	0.000171	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP19A1—esophageal cancer	3.65e-05	0.00017	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ADH7—esophageal cancer	3.58e-05	0.000167	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLCE1—esophageal cancer	3.58e-05	0.000167	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.54e-05	0.000165	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMP—esophageal cancer	3.51e-05	0.000163	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—esophageal cancer	3.45e-05	0.000161	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOS3—esophageal cancer	3.44e-05	0.00016	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP26A1—esophageal cancer	3.41e-05	0.000159	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMOX1—esophageal cancer	3.33e-05	0.000155	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALOX15—esophageal cancer	3.33e-05	0.000155	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—esophageal cancer	3.22e-05	0.00015	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—esophageal cancer	3.2e-05	0.000149	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TPI1—esophageal cancer	3.17e-05	0.000148	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTO1—esophageal cancer	3.17e-05	0.000148	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ADH1B—esophageal cancer	3.14e-05	0.000146	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDOB—esophageal cancer	3.04e-05	0.000142	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMP—esophageal cancer	3e-05	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—esophageal cancer	2.99e-05	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.93e-05	0.000136	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP26A1—esophageal cancer	2.92e-05	0.000136	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.9e-05	0.000135	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—esophageal cancer	2.84e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALOX15—esophageal cancer	2.84e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNG7—esophageal cancer	2.76e-05	0.000129	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—esophageal cancer	2.75e-05	0.000128	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTO1—esophageal cancer	2.71e-05	0.000126	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TPI1—esophageal cancer	2.71e-05	0.000126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—esophageal cancer	2.62e-05	0.000122	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDOB—esophageal cancer	2.6e-05	0.000121	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDH2—esophageal cancer	2.59e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GAPDH—esophageal cancer	2.5e-05	0.000117	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CRABP1—esophageal cancer	2.48e-05	0.000115	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTT1—esophageal cancer	2.46e-05	0.000115	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2A6—esophageal cancer	2.43e-05	0.000113	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.42e-05	0.000113	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNG7—esophageal cancer	2.36e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO1—esophageal cancer	2.31e-05	0.000107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS1—esophageal cancer	2.31e-05	0.000107	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—esophageal cancer	2.28e-05	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSME2—esophageal cancer	2.27e-05	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSME1—esophageal cancer	2.27e-05	0.000106	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—esophageal cancer	2.23e-05	0.000104	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDH2—esophageal cancer	2.21e-05	0.000103	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CREBBP—esophageal cancer	2.14e-05	9.95e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.1e-05	9.79e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.08e-05	9.68e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.07e-05	9.64e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.98e-05	9.24e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO1—esophageal cancer	1.97e-05	9.17e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.97e-05	9.17e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.96e-05	9.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSME2—esophageal cancer	1.94e-05	9.04e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSME1—esophageal cancer	1.94e-05	9.04e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—esophageal cancer	1.94e-05	9.01e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NOS3—esophageal cancer	1.91e-05	8.91e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—esophageal cancer	1.87e-05	8.72e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.84e-05	8.58e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—esophageal cancer	1.75e-05	8.15e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.7e-05	7.89e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.68e-05	7.83e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.68e-05	7.8e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.65e-05	7.68e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.61e-05	7.52e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.57e-05	7.33e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—esophageal cancer	1.45e-05	6.77e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.44e-05	6.69e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.41e-05	6.57e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.38e-05	6.42e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.22e-05	5.68e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.08e-05	5.02e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.08e-05	5.01e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.04e-05	4.86e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NOS3—esophageal cancer	9.66e-06	4.5e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CREBBP—esophageal cancer	9.22e-06	4.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—esophageal cancer	8.83e-06	4.11e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NOS3—esophageal cancer	8.25e-06	3.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—esophageal cancer	7.55e-06	3.52e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—esophageal cancer	7.35e-06	3.42e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—esophageal cancer	6.28e-06	2.92e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—esophageal cancer	5.44e-06	2.53e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—esophageal cancer	4.64e-06	2.16e-05	CbGpPWpGaD
